We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SLQT:NYSESelectQuote, Inc. Analysis

Data as of 2026-05-01 - not real-time

$0.92

Latest Price

8/10Risk

Risk Level: High

Executive Summary

SelectQuote trades at $0.92, well below its DCF‑derived fair value of $0.58 with an implied upside of over 230%, indicating a deep discount. The technical picture shows a bullish MACD crossover and an RSI of 65, suggesting momentum is still positive but approaching overbought territory. Volume has been increasing, and the price sits comfortably above the identified support level of $0.58, while the broader trend remains neutral. However, the stock exhibits a very high 30‑day volatility of 71% and a beta above 2.0, underscoring significant price swings. Recent news notes a **54% rebound** over the past month, yet the stock remains highly speculative with a 72% loss year‑to‑date.
Fundamentally, SLQT posted revenue of $1.62 billion with 11.6% growth, a gross margin near 35% and operating margin of 14%. Forward earnings are projected to rebound sharply, reflected in a forward EPS of $0.21 and a forward P/E of 4.38, far below the industry average of ~17.6. The balance sheet is strained, featuring a debt‑to‑equity of 70% and minimal cash, and the company does not pay a dividend. Given the sizable upside potential, strong revenue growth outlook, but pronounced volatility and leverage, the stock sits at a crossroads between speculative upside and heightened risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bullish MACD and rising volume suggest short‑term momentum
  • Price remains above key support, limiting immediate downside
  • High volatility and beta increase risk of rapid moves

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation gap with DCF fair value and 230% upside
  • Revenue growth of >10% and improving forward earnings estimates
  • Low price‑to‑book and price‑to‑sales multiples relative to peers

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Regulatory exposure in Medicare and health insurance markets
  • Elevated leverage and limited cash cushion
  • Sustained high beta and volatility may dampen long‑term returns

Key Metrics & Analysis

Financial Health

Revenue Growth11.60%
Profit Margin4.80%
P/E Ratio4.4
ROE16.44%
ROA2.30%
Debt/Equity70.37
P/B Ratio0.5
Op. Cash Flow$12.1M
Free Cash Flow$24.0M
Industry P/E17.6

Technical Analysis

TrendNeutral
RSI65.4
Support$0.58
Resistance$1.02
MA 20$0.77
MA 50$0.74
MA 200$1.49
MACDBullish
VolumeIncreasing
Fear & Greed Index90.89

Valuation

Fair Value$0.58
Target Price$3.06
Upside/Downside232.95%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta2.10
Volatility71.44%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.